AcelRx Pharmaceuticals, Inc. (ACRX) Stock Price Down 59.8%

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was down 59.8% on Thursday . The company traded as low as $2.00 and last traded at $2.15. Approximately 24,236,722 shares changed hands during mid-day trading, an increase of 1,211% from the average daily volume of 1,849,080 shares. The stock had previously closed at $5.35.

A number of equities research analysts have weighed in on ACRX shares. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. Royal Bank Of Canada set a $6.00 price objective on AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. Roth Capital reiterated a “buy” rating and issued a $12.50 price objective on shares of AcelRx Pharmaceuticals in a research note on Thursday, August 10th. Stifel Nicolaus upgraded AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Friday, August 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $8.00.

The company’s market capitalization is $97.57 million. The company has a 50 day moving average of $3.80 and a 200-day moving average of $2.97.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.01). The business had revenue of $2.66 million during the quarter, compared to analysts’ expectations of $2.63 million. On average, equities analysts forecast that AcelRx Pharmaceuticals, Inc. will post ($1.13) EPS for the current fiscal year.

In other news, CEO Vincent J. Angotti acquired 15,000 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were bought at an average price of $3.00 per share, with a total value of $45,000.00. Following the purchase, the chief executive officer now owns 15,000 shares of the company’s stock, valued at $45,000. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Lawrence G. Hamel sold 10,161 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $5.29, for a total value of $53,751.69. Following the completion of the sale, the insider now directly owns 16,379 shares in the company, valued at approximately $86,644.91. The disclosure for this sale can be found here. Insiders bought a total of 37,000 shares of company stock worth $112,280 in the last three months. Company insiders own 28.10% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of ACRX. Teachers Advisors LLC raised its stake in shares of AcelRx Pharmaceuticals by 14.6% in the 4th quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 8,475 shares in the last quarter. Virtu KCG Holdings LLC raised its stake in shares of AcelRx Pharmaceuticals by 600.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 101,742 shares in the last quarter. LMR Partners LLP bought a new stake in shares of AcelRx Pharmaceuticals in the 2nd quarter worth $319,000. Bank of New York Mellon Corp raised its stake in shares of AcelRx Pharmaceuticals by 6.6% in the 1st quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after buying an additional 6,942 shares in the last quarter. Finally, WealthTrust Axiom LLC raised its stake in shares of AcelRx Pharmaceuticals by 50.0% in the 2nd quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock worth $451,000 after buying an additional 70,000 shares in the last quarter. 23.32% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “AcelRx Pharmaceuticals, Inc. (ACRX) Stock Price Down 59.8%” was originally posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.thestockobserver.com/2017/10/12/acelrx-pharmaceuticals-inc-acrx-stock-price-down-59-8.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply